TQ Course | Review of Systems (Orlando 2022) by Optometric Education Consultants | May 20, 2022 | 2022 Orlando, TQ Courses | 0 comments HiddenReview of SystemsHiddenDate (Hidden) MM slash DD slash YYYY HiddenEvent Date (Hidden) MM slash DD slash YYYY HiddenEvent 60 days past date (Hidden) MM slash DD slash YYYY HiddenEvent Date Difference (Hidden)1. Which of the following is the most common source of cardiac emboli to the eye?* A. Cardiac valves B. Aorta C. Pulmonary artery D. Coronary arteries 2. What is the most common cause of death in the United States?* A. Stroke B. Myocardial infarction C. Cancer D. Pneumonia 3. Bilateral involvement in patients with ocular ischemic syndrome may occur in up to of cases.* A. 5%. B. 20%. C. 42%. D. 58%. 4. The most common etiology of ocular ischemic syndrome is severe unilateral or bilateral atherosclerotic disease of the _______.* A. Internal carotid artery B. Vertebral artery C. Posterior cerebral artery D. Brachial artery 5. What is the most commonly used non-invasive imaging test to detect carotid occlusive disease?* A. Trans-thoracic echocardiography B. Magnetic resonance angiography (MRA) C. Multi-focal electroretinography D. Duplex (Doppler) carotid ultrasonography 6. A granulomatous condition is characterized by an organized collection of:* A. Macrophages B. Eosinophils C. Histamine D. Tumor cells 7. In the ocular ischemic syndrome/hypoperfusion retinopathy, the majority of hemorrhages occur in which area of the retina?* A. Mid-periphery B. Posterior pole C. Far periphery D. Fovea 8. The eye is an extension of __________.* A. The brain and central nervous system B. The skeletal system C. The digestive system D. The excretory system 9. Which patient is most likely to have sarcoidosis?* A. 9-year-old black female B. 28-year-old black female C. 28-year-old white male D. 55-year-old white female 10. Which of the following best describes sarcoidosis?* A. A cardiac disease B. A pulmonary disease C. A multi-system disease D. An ocular disease 11. Pernicious Anemia results from a lack of absorption of ________* A. Vitamin B12 B. Vitamin A C. Vitamin C D. Vitamin D 12. Anemic Retinopathy may be characterized by white-centered hemorrhages known as .* A. Roth spots B. Elschnig’s spots C. Mittendorf’s dots D. Histo spots 13. The most prevalent variant of sickle-cell disease is ________.* A. Sickle cell anemia B. Sickle ß-thalassemia C. SC disease D. Sickle cell trait 14. Proliferative sickle cell retinopathy is characterized by _________?* A. Venous tortuosity peripheral vessels B. Salmon patch hemorrhages C. Black sunbursts D. Sea-fan neovascularization 15. Enlarged lymph nodes are a clinical manifestation of _________?* A. Acute myelogenous leukemia (AML) B. Sickle cell trait C. Iron deficient anemia D. Pernicious anemia 16. Which factor is least likely to contribute to the development of hypertension?* A. sex B. ethnicity C. eye color D. age 17. You perform blood pressure on a 55-year old Hispanic male during a comprehensive eye examination. The results are 135/90 mmHg RAS @ 3:35PM. What should you do next?* A. enucleate the right eye B. refer to the Emergency Room STAT! C. finish the eye exam and have patient to schedule an appointment with his general doctor within the next 2 months D. perform gonioscopy 18. Hypertensive choroidopathy may be characterized by _______.* A. Sub-retinal neovascularization B. Schie’s line C. Drusen D. Elschnig’s spots 19. Which of the following is a common ocular manifestation of high blood pressure?* A. flame shaped hemes B. vitreomacular traction syndrome (VMTS) C. angle closure glaucoma D. drusen 20. At what grade does one typically observe retinal hemorrhages in association with hypertensive retinopathy?* A. Pre-hypertensive stage B. Stage 1 C. Stage 2 D. Stage 3 21. What is the most frequently encountered and primary manifestation of hypertensive retinopathy?* A. blot hemorrhages B. arteriolosclerosis C. exudative macular star D. optic nerve swelling 22. The best ocular treatment/management approach for patients with Stage 1-3 hypertensive retinopathy is _________.* A. Ranibizumab (Lucentis) intravitreal injection B. Laser photocoagulation C. Systemic hypertension management (blood pressure control) D. Vitrectomy Personal InformationName* First Last Email* Phone*OE Tracker # License # Address* Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongo, Democratic Republic of theCongo, Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzech RepublicCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatini (Swaziland)EthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacauMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth KoreaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussiaRwandaRéunionSaint BarthélemySaint HelenaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth GeorgiaSouth KoreaSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan Mayen IslandsSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaVietnamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Payment InformationHiddenRetake Code Review of Systems | TQ Credit*After 8/11/2022, pricing will increase to $30. Price: (Past 60 Days) Review of Systems | TQ CreditThis course was presented over 60 days ago. Due to this late submission of TQ, your TQ credit price is $30. Price: Retake Discount Price: (Past 60 Days) Retake Discount Price: Payment MethodPayPal Checkout MasterCardVisaSupported Credit Cards: MasterCard, Visa Card Number Expiration Date Security Code Cardholder Name HiddenCourse Information (HIDDEN)HiddenCourse Name (HIDDEN) HiddenRetake Code (HIDDEN) HiddenQuiz URL (HIDDEN)Do not include ending backslash (aka no .com/) HiddenCE Hours Submit a Comment Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website
